Cognition – Talk Bio

Atai’s Schizophrenia Drug Fails to Improve Cognition in Phase 2 Study

2 months ago talkbio0Tagged Atai Life Sciences, CIAS, clinical endpoints, Clinical trial failure, Cognition, Impaired cognition, inidascamine, Recognify Life Sciences, Schizophrenia

Atai Life Sciences; Recognify Life Sciences; inidascamine; schizophrenia; cognitive impairment; Phase 2b trial; clinical trial failure; cognition; CIAS; clinical endpoints

Cognition Therapeutics’ Stock Plummets After Alzheimer’s Drug Misses Cognitive Endpoint

1 year ago talkbio0Tagged Alzheimer 's disease, Clinical Trials, Cognition, cognitive endpoint, decline

Cognition Therapeutics, Alzheimer’s disease, cognitive endpoint, stock decline, clinical trial

Annovis Bio Reports Promising Phase III Study Results for Buntanetap in Parkinson’s Disease Treatment

1 year ago talkbio0Tagged Annovis, Bio, buntanetap, Cognition, MDS-UPDRS, Motor function (observable entity), Neurodegenerative Disorders, Parkinson 's disease, Parkinson 's Disease Rating Scale, Phase 3 Clinical Trials, Unified - Type of Agreement

Annovis Bio, Buntanetap, Parkinson’s Disease, Phase III Study, Neurodegenerative Disorders, Cognitive Function, Motor Functions, Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)